Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Issue 1 (12th January 2023)

• Record Type: Journal Article
• Authors: Son, Kiho; Jamil, Rameen; Chowdhury, Abhiroop; Mukherjee, Manan; Venegas, Carmen; Miyasaki, Kate; Zhang, Kayla; Patel, Zil; Salter, Brittany; Yuen, Agnes Che Yan; Lau, Kevin Soon-Keen; Cowbrough, Braeden; Radford, Katherine; Huang, Chynna; Kjarsgaard, Melanie; Dvorkin-Gheva, Anna; Smith, James; Li, Quan-Zhen; Waserman, Susan; Ryerson, Christopher J.; Nair, Parameswaran; Ho, Terence; Balakrishnan, Narayanaswamy; Nazy, Ishac; Bowdish, Dawn M.E.; Svenningsen, Sarah; Carlsten, Chris; Mukherjee, Manali
• Is Part Of: European respiratory journal. Volume 61:Issue 1(2023)
• Publication Date: 2023-01-12
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00970-2022
• Languages: English
• ISSNs: 0903-1936

Abstract

Background: Autoimmunity has been reported in patients with severe coronavirus disease 2019 (COVID-19). We investigated whether anti-nuclear/extractable-nuclear antibodies (ANAs/ENAs) were present up to a year after infection, and if they were associated with the development of clinically relevant post-acute sequalae of COVID-19 (PASC) symptoms. Methods: A rapid-assessment line immunoassay was used to measure circulating levels of ANAs/ENAs in 106 convalescent COVID-19 patients with varying acute phase severities at 3, 6 and 12 months post-recovery. Patient-reported fatigue, cough and dyspnoea were recorded at each time point. Multivariable logistic regression model and receiver operating curves were used to test the association of autoantibodies with patient-reported outcomes and pro-inflammatory cytokines. Results: Compared to age- and sex-matched healthy controls (n=22) and those who had other respiratory infections (n=34), patients with COVID-19 had higher detectable ANAs at 3 months post-recovery (p<0.001). The mean number of ANA autoreactivities per individual decreased between 3 and 12 months (from 3.99 to 1.55) with persistent positive titres associated with fatigue, dyspnoea and cough severity. Antibodies to U1-snRNP and anti-SS-B/La were both positively associated with persistent symptoms of fatigue (p<0.028, area under the curve (AUC) 0.86) and dyspnoea (p<0.003, AUC=0.81). Pro-inflammatory cytokines such as tumour necrosis factor (TNF)-α and C-reactive protein predicted the elevated ANAs at 12 months. TNF-α, D-dimer and interleukin-1β had the strongest association with symptoms at 12 months. Regression analysis showed that TNF-α predicted fatigue (β=4.65, p=0.004) and general symptomaticity (β=2.40, p=0.03) at 12 months. Interpretation: Persistently positive ANAs at 12 months post-COVID are associated with persisting symptoms and inflammation (TNF-α) in a subset of COVID-19 survivors. This finding indicates the need for further investigation into the role of autoimmunity in PASC. Circulating antinuclear autoantibodies were detected in COVID-19 patients up to 12 months post-recovery. The presence of these autoantibodies was associated with persisting symptoms and residual inflammation. https://bit.ly/3AduU02